Sai Parenterals Ltd subsidiary to acquire majority stake in Bion Therapeutics’ prescription business
- SP Analytics signed a definitive agreement for an all-cash transaction, expected to close before end-November 2026.
- Bion brings 16 established brands, about 250 field staff, coverage across 12 states and a network serving around 20,000 doctors.
- Funding will come from internal accruals, debt and part of IPO proceeds allocated for general corporate purposes; Bion’s management team will continue to lead the business.
